---
figid: PMC5941661__10.1177_1753466618767611-fig1
figtitle: Dabrafenib and trametinib acting on the MAPK pathway
organisms:
- Homo sapiens
pmcid: PMC5941661
filename: 10.1177_1753466618767611-fig1.jpg
figlink: /pmc/articles/PMC5941661/figure/fig1-1753466618767611/
number: F1
caption: 'Mechanism of action of dabrafenib and trametinib: binding of BRAF and MEK
  inhibitors generates a blockade point in MAPK pathway at two different levels, inhibiting
  oncogenic downstream signaling and causing cell cycle arrest.MAPK: mitogen-activated
  protein kinase.'
papertitle: 'Dabrafenib in combination with trametinib in the treatment of patients
  with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical
  evidence and experience.'
reftext: Arjun Khunger, et al. Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618767611.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9690469
figid_alias: PMC5941661__F1
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC5941661__F1
ndex: 4e1e5ea9-dec8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5941661__10.1177_1753466618767611-fig1.html
  '@type': Dataset
  description: 'Mechanism of action of dabrafenib and trametinib: binding of BRAF
    and MEK inhibitors generates a blockade point in MAPK pathway at two different
    levels, inhibiting oncogenic downstream signaling and causing cell cycle arrest.MAPK:
    mitogen-activated protein kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAF EDabrafenib
  - Trametinib
  - ESCH772984
---
